ORB-011 Immunotherapy Begins Phase I Trials

In a breakthrough partnership, ChemDiv Inc., a prominent drug discovery platform provider, and Orionis Biosciences have reached a critical juncture with the launch of Phase I clinical trials for a novel immunotherapy drug, ORB-011. This state-of-the-art compound represents a significant stride in the field of medicine, particularly in cancer treatment.

Derived from Orionis' groundbreaking A-Kine® platform, ORB-011 is a result of meticulous research and development, supported by ChemDiv's advanced chemistry and biology tools. The drug is designed to selectively activate cDC1 dendritic cells, which are crucial for presenting tumor antigens, thereby enhancing the body's immune response to cancer. By utilizing ChemDiv's expertise in developing potent 'warheads', ORB-011 aims to maximize the therapeutic effects of interferons while reducing the systemic side effects often associated with cytokine therapies.

Bill Farley, CEO of ChemDiv, expressed his pride in the collaboration with Orionis Biosciences, highlighting the clinical trial's commencement as a pivotal moment in the pharmaceutical industry. He emphasized the importance of this development in the realm of immunobiology and the hope it brings for a transformative approach to cancer treatments.

The Phase I clinical trials signify a major step forward in the collaborative efforts between ChemDiv and Orionis Biosciences. Their joint research is expected to pave the way for innovative drug discoveries that could significantly improve patient outcomes in cancer therapy.

ChemDiv, with its extensive experience spanning over 30 years, is renowned for providing comprehensive R&D services to the pharmaceutical industry. The company is dedicated to delivering innovative leads, drug candidates, and new drugs across a wide range of therapeutic areas to partners around the globe.

ChemDiv's commitment to advancing pharmaceutical solutions and its collaborative spirit with Orionis Biosciences exemplify the potential for scientific synergy to yield groundbreaking treatments. The journey of ORB-011 from concept to clinical trials is a testament to the power of focused research and the relentless pursuit of medical advancements.